The following is a summary of the terms of the notes offered by the preliminary pricing supplement highlighted below.
Summary of Terms

Issuer:
Guarantor:
Minimum Denomination:
Index:
Pricing Date:
Observation Date:
Maturity Date:
Maximum Upside Return:

## Buffer Amount:

Payment At Maturity:

JPMorgan Chase Financial Company LLC
JPMorgan Chase \& Co.
\$1,000
S\&P $500^{\circ}$ Index and Russell $2000^{\circ}$ Index
May 27, 2021
June 28, 2022
July 1, 2022
At least $9.00 \%$,
10.00\%

If the Final Value of each Index is greater than its Initial Value, your payment at maturity per S1,000 principal amount note will be calculated as follows:
$\$ 1,000+(\$ 1,000 \times$ Lesser Performing Index Return), subject to the Maximum Upside Return
If (i) the Final Value of one Index is greater than its Initial Value and the Final Value of the other Index is equal to its Initial Value or is less than its Initial Value by up to the Buffer Amount or (ii) the Final Value of each Index is equal to its Initial Value or is less than its Initial Value by up to the Buffer Amount, your payment at maturity per $\$ 1,000$ principal amount note will be calculated as follows:
$1,000+(\$ 1,000 \times$ Absolute Index Return of the Lesser Performing Index)
This payout formula resuits in an effective cap of $10.00 \%$ on your retum at maturity if the Lesser Performing Index Return is negative. Under these limited circumstances, your maximum payment at maturity is $\$ 1,100.00$ per $\$ 1,000$ principal amount note
If the Final Value of either Index is less than its Initial Value by more than the Buffer Amount, your payment at maturity per $\$ 1,000$ principal amount note will be calculated as follows:

$$
\$ 1,000+[\$ 1,000 \times \text { (Lesser Performing Index Return + Buffer Amount) }]
$$

If the Final Value of either Index is less than its Initial Value by more than the Buffer Amount, you will lose some or most of your principal amount at maturity. 48132T5C6
CUSIP:
Preliminary Pricing
Supplement:
htip/nspipmorgan comidocumenucusipha132T5C8idoctyper Product Term mated value of the notes, when the terms of the notes are set, will not be less than $\$ 900.00$ per price you paid for the notes, please see the hyperlink above
Any paymert on the notes is subjoct to the credit nisk of JPM Morgan Chase Financial Compary LLC, as issuer of the notes, and the credit risk of JPMMergan Chase 8 CO . as quarantor of the notes.

- The actual Maximum Upside Return will be provided in the pricing supplement and will not be less than $9.00 \%$
"Reflects Maximum Lpside Retum equal to the minimum Maximum Upside Retum set forth herein, for illustrative purposes.
The "total return" as used above is the number, expressed as a percentage, that results from comparing the paymert at maturity par $\$ 1,000$ principal amourt nate
$10 \$ 1,000$.
The hypothetical returns shown above apply cnly at matuity. These hypotheticals do not reflect fees or expenses that would be associated with any sale in the secondary market. It these tees and expenses wece included, the thypothetical returns shown showe would likely be lower:


## Hypothetical Total Returns**

| snse |  |  |
| :--- | :--- | :--- |

## 13mo Capped Dual Directional Buffered Equity Notes linked to Lesser Performing of SPX/RTY

## Selected Risks

- Your investment in the notes may result in a loss. The notes do not guarantee any return of principal.
- Your maximum gain on the notes is limited to the Maximum Upside Retum if the Lesser Performing Index Return is positive
* Your maximum gain on the note is limited by the Buffer Amount if the Lesser Performing Index Return is negative.
* Any payment on the notes is subject to the credit risks of JPMorgan Financial Company LLC and JPMorgan Chase \& Co. Therefore the value of the notes prior to maturity will be subject to changes in the market's view of the creditworthiness of JPMorgan Chase Financial Company LLC or JPMorgan Chase \& Co.
- You are exposed to the risk of decline in the level of each Index.
- Your payment at maturity will be determined by the Lesser Performing Index.
* No interest payment, dividend payments or voting rights.
- JPMorgan Chase \& Co. is currently one of the companies that make up the S\&P 500 ${ }^{*}$ Index.
- The notes are subject to the risks associated with small capitalization companies.
- As a finance subsidiary, JPMorgan Chase Financial Company LLC has no independent operations and has limited assets.


## Selected Risks (continued)

- The estimated value of the notes will be lower than the original issue price (price to public) of the notes.
- The estimated value of the notes is determined by reference to an internal funding rate.
- The estimated value of the notes does not represent future values and may differ from others' estimates.
- The value of the notes, which may be reflected in customer account statements, may be higher than the then current estimated value of the notes for a limited time period.
- Lack of liquidity: J.P. Morgan Securities LLC (who we refer to as JPMS) intends to offer to purchase the notes in the secondary market but is not required to do so. The price, if any, at which JPMS will be willing to purchase notes from you in the secondary market, if at all, may result in a significant loss of your principal.
- Potential conflicts: We and our affiliates play a variety of roles in connection with the issuance of notes, including acting as calculation agent and hedging our obligations under the notes, and making the assumptions used to determine the pricing of the notes and the estimated value of the notes when the terms of the notes are set. It is possible that such hedging or other trading activities of J.P. Morgan or its affiliates could result in substantial retums for J.P. Morgan and its affiliates while the value of the notes decline.
- The tax consequences of the notes may be uncertain. You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes.

The risks identified above are not exhaustive. Please see "Risk Factors" in the applicable product supplement and underlying supplement and "Selected Risk Considerations" in the applicable preliminary price supplement for additional information.

## Additional Information

SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase \& Co. have filed a registration statement (including a prospectus) with the SEC for any offerings to which these materials relate. Before you invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPMorgan Chase Financial Company LLC and JPMorgan Chase \& Co. has filed with the SEC for more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase \& Co. and this offering. You may get these documents vithout cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively. JPMorgan Chase Financial Company LLC and JPMorgan Chase \& Co., any agent or any dealer participating in the this offering will arrange to send you the prospectus and each prospectus supplement as well as any product supplement, underfying supplement and preliminary pricing supplement if you so request by calling toll-free 1-866-535-9248.

IRS Circular 230 Disclosure: JPMorgan Chase \& Co, and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters contained herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone unaffiliated with JPMorgan Chase \& Co, of any of the matters address herein or for the purpose of avoiding U.S. taxrelated penalties

Investment suitability must be determined individually for each investor, and the financial instruments described herein may not be suitable for all investors. This information is not intended to provide and should not be relied upon as providing accounting, legal, regulatory or tax advice. Investors should consult with their own advisors as to these matters.
This material is not a product of J.P. Morgan Research Departments.
Free Writing Prospectus Filed Pursuant to Rule 433, Registration Statement Nos. 333-236659 and 333-236659-01

